<DOC>
	<DOCNO>NCT01116895</DOCNO>
	<brief_summary>An international , multi-centre , prospective , randomised , double-blind , 4-arm , placebo control , parallel group study 12 week daily oral treatment subject psoriasis vulgaris .</brief_summary>
	<brief_title>A Proof Concept Study Comparing Three Doses Oral Solution LEO 22811 With Placebo Oral Solution Treatment Psoriasis Vulgaris</brief_title>
	<detailed_description />
	<mesh_term>Psoriasis</mesh_term>
	<criteria>Following verbal write information trial subject must provide sign date informed consent study related activity carry , include activity relate washout period . Clinical diagnosis psoriasis vulgaris , least 6 month prior randomisation , currently cover least 10 % body surface area ( BSA ) Candidates systemic antipsoriatic treatment Psoriasis Area Severity Index ( PASI ) â‰¥10 Disease severity moderate , severe severe accord Investigators ' Global Assessment disease severity ( IGA ) Aged 18 year Any race ethnicity Males , surgically sterile female ( bilateral tubal ligation , bilateral oophorectomy hysterectomy ) post menopausal female ( least 1 year since last menses ) Attending hospital outpatient clinic private practice dermatologist Systemic treatment biological therapy whether market possible effect psoriasis vulgaris within follow time period prior randomisation : Etanercept 4 week Adalimumab , alefacept , infliximab 2 month Ustekinumab 4 month Systemic treatment therapy ( biologics ) possible effect psoriasis vulgaris ( e.g.corticosteroids , retinoids , immunosuppressant , methotrexate , cyclosporin fumaric acid ) within 4 week prior randomisation PUVA therapy within 4 week prior randomisation UVB therapy within 2 week prior randomisation Any topical treatment ( except emollients/ medicate shampoo ) within 2 week prior randomisation Initiation , change concomitant medication could affect psoriasis vulgaris ( e.g . betablockers , antimalaria drug , lithium ) 2 week prior randomisation study Current diagnosis erythrodermic , exfoliative pustular psoriasis Other current skin condition may confound evaluation psoriasis vulgaris judge Investigator Generally good health clinically significant cardiac , endocrinologic , pulmonary , neurologic , psychiatric , hepatic , renal , haematologic , gastrointestinal disease , immunologic insufficiency , major disease current condition , opinion Investigator , would put subject risk participate study Current active tuberculosis latent tuberculosis Planned exposure sun study may affect psoriasis vulgaris Known malignancy history malignancy ( cervical carcinoma situ , basal cell squamous cell carcinoma ) within 5 year period prior randomisation Live vaccination within 4 week prior randomisation Males agree use adequate contraception study ( include followup ) ensure partner become pregnant Known suspect hypersensitivity component ( ) investigational product Current participation interventional trial Treatment nonmarketed drug substance ( i.e . agent yet make available clinical use follow registration ) within 4 week 5 halflives ( whichever longer ) prior randomisation Previously randomise study Known , opinion Investigator , unlikely comply Clinical Study Protocol ( e.g. , alcohol abuse , drug dependency psychotic state ) .</criteria>
	<gender>All</gender>
	<minimum_age>18 Years</minimum_age>
	<maximum_age>N/A</maximum_age>
	<verification_date>September 2011</verification_date>
	<keyword>Psoriasis Vulgaris</keyword>
	<keyword>Systemic</keyword>
	<keyword>Anti-psoriatic</keyword>
</DOC>